Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy

Conditions

• Fibroids, Uterine
• Fluid Deficit
• Hysteroscopy / Methods

Eligibility Criteria

Sex

FEMALE

Age

18 Years - 50 Years

Healthy Volunteers

Not accepted

Interventions

• Misoprostol Tabets — DRUG
  800 mcg of misoprostol will be administered per rectum to intervention group prior to their scheduled hysteroscopic myomectomy.
• Placebo — DRUG
  4 tablets of Zeebo (Microcsrystalline cellulose) placebo tablets will be placed per rectum to prior to undergoing a hysteroscopic myomectomy, for patients assigned to the placebo arm.

Study Details

The goal of this double blinded randomized control trial is to evaluate the impact of misoprostol on fluid deficit during hysteroscopic myomectomies. The main questions it aims to answer are: Is there is difference in fluid deficit in patients who receive misoprostol vs placebo pre operatively for hysteroscopic myomectomies? Participants will be randomized to received 800 mcg of either rectal misoprostol prior to their hysteroscopic myomectomy or 4 tablets of placebo (ZEEBO) prior to their hysteroscopic myomectomy.

Key Dates

Start date

Dec 16, 2025

Status verified

May 2026

Primary completion

Dec 31, 2026

Completion

Dec 31, 2026

Study Design

Enrollment

40 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Misoprostol (treatment aem)
  Patients will received 800 mcg of misoprostol per rectum prior to procedure.
• Placebo Comparator: Zeebo (Placebo arm)
  Patient will receive 4 tablets of placebo (ZEEBO) per rectum prior to procedure.

Primary Outcome Measure

Fluid Deficit [ Time Frame: Immediately at the conclusion of the procedure. ]

Central Contacts

• Hannah Pope, MD
  3126946773
  [email protected]
• Juan Avitia, MPH
  [email protected]

Locations (1)

Find similar trials in Chicago, IL